Probiotic
Dietary SupplementParticipants will be instructed to take one capsule once daily in the morning with a meal and water.
NCT Number: NCT07751614
This randomized, double-blind, placebo-controlled pilot study will evaluate the effects of four weeks of supplementation with a probiotic on mental health in healthy adults aged 18-30 years. Participants will be randomized to receive either probiotic or placebo and will complete study assessments at baseline and end of intervention, and will complete a range of behavioral, physiological, and questionnaire-based assessments before and after the intervention. The primary objective is to assess the effect on emotional reactivity measured in a virtual reality scenario at the end of the intervention. This exploratory study is intended to generate data to inform future clinical research.
Trial opening soon.
Get Notified18 year–30 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be instructed to take one capsule once daily in the morning with a meal and water.
Participants will be instructed to take one capsule once daily in the morning with a meal and water.
Time frame: This outcome is assessed only at treatment completion (at week 4).
Participants complete a virtual reality-based assessment (VIRDIS) and rate their level of unpleasantness following exposure to a predefined social scenario. Unpleasantness is assessed on a 5-point scale ranging from 1 (not at all unpleasant) to 5 (very unpleasant).
Time frame: This outcome is assessed only at treatment completion (at week 4)
This outcome comprises the mean unpleasantness score across all VR scenarios in the VIRDIS test on a scale ranging from 1 (not at all unpleasant) to 5 (very unpleasant).
Time frame: This outcome is assessed only at treatment completion (at week 4).
Heart rate is measured during the VIRDIS assessment (using a wearable physiological monitoring device). Heart rate (pulse) is reported in beats per minute (bpm). Higher scores indicating higher heart rate.
Time frame: Change from baseline to treatment completion (at week 4)
The SF-36 questionnaire will be administered in its entirety. The Energy/Vitality subscale (items 23, 27, 29, and 31) is designated as a secondary outcome measure.
Time frame: This outcome is assessed only at treatment completion (at week 4).
Heart rate variability is measured during the VIRDIS assessment (using a wearable physiological monitoring device). HRV is derived from the variation in time between consecutive heartbeats (interbeat intervals).
Time frame: This outcome is assessed only at treatment completion (at week 4).
Skin conductance (electrodermal activity) measured during the VIRDIS assessment. Outcomes include tonic and phasic skin conductance measures reported in microsiemens (µS).
Time frame: This outcome is assessed only at treatment completion (at week 4).
Pupil dilation is measured during the VIRDIS assessment using integrated eye-tracking technology. The outcome is reported as change in pupil diameter (mm).
Time frame: This outcome is assessed only at treatment completion (at week 4).
Eye-tracking technology integrated into the VIRDIS assessment records gaze behavior during the virtual reality scenarios. This outcome is reported as the mean gaze velocity (°/s), i.e., average angular velocity of eye movements recorded throughout the virtual reality assessment. Unit of measure: degrees/second (°/s).
Time frame: This outcome is assessed only at treatment completion (at week 4).
Eye-tracking technology integrated into the VIRDIS assessment records mean saccade amplitude in the virtual reality scenarios measures as the average angular distance of saccadic eye movements (i.e., rapid eye movement between two points of focus). Unit of measure: degrees
Time frame: Change from baseline to treatment completion (at week 4).
The SF-36 is a self-administered quality of life questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as physical component summary and mental component summary. The norm data is 0-100, the health-related quality of life increases as the scores increase. The average score is 50.
Time frame: Change from baseline to treatment completion (at week 4).
Questionnaire on quality of life. Part A score range: 5-15. Part B: VAS scale: 0-100.
Time frame: Change from baseline to treatment completion (at week 4)
Questionnaire assessing subjective sleep quality. Outcomes include the global PSQI score (range 0-21) and the seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Higher scores indicate poorer sleep quality.
Time frame: Change from baseline to treatment completion (at week 4)
Questionnaire on perceived stress. Score range 0-40.
Time frame: Change from baseline to treatment completion (at week 4)
Questionnaire on depressive symptoms. Score range 0-72.
Time frame: Change from baseline to treatment completion (at week 4)
Questionnaire on cognitive difficulties. Score range 0-48.
Time frame: Change from baseline to treatment completion (at week 4).
Questionnaire on anxiety. Score range 20-80.
Time frame: Change from baseline to treatment completion (at week 4)
Questionnaire on attentional control. Score range 12-48.
Time frame: Change from baseline to treatment completion (at week 4)
Questionnaire on emotion regulation. Score range 7-49.
Time frame: Change from baseline to treatment completion (at week 4)
Questionnaire on emotion regulation. Score range 0-144.
Time frame: Change from baseline to treatment completion (at week 4)
Questionnaire on emotion regulation. Score range 0-72.
Time frame: This outcome is assessed only at treatment completion (at week 4)
Computerized test assessing visuospatial memory and new learning. The main outcome is the total number of errors (incorrect boxes selected) made across all stages, adjusted to account for stages not completed.
Time frame: This outcome is assessed only at treatment completion (at week 4).
A computerised neuropsychological test assessing sustained attention. The outcome measure is A-prime (A'), which measures target sensitivity (sustained attention). score range 0-1.
Time frame: This outcome is assessed only at treatment completion (at week 4).
A computerised neuropsychological test assessing spatial working memory. The main outcome is the number of times a participant revisits a box that has already been opened and found to be empty in a specific trial.
Time frame: This outcome is assessed only at treatment completion (at week 4).
A computerized emotional processing task in which participants categorize positive and negative personality trait words according to whether they would like or dislike being described by each characteristic. Following the categorization task, participants are asked to recall as many words as possible.
Time frame: This outcome is assessed only at treatment completion (at week 4).
Computerized emotional processing task assessing valence bias during evaluation of emotional facial expressions. The primary outcome is valence bias, defined as the percentage of ambiguous surprised faces rated as "bad."
Time frame: This outcome is assessed only at treatment completion (at week 4).
Computerized task assessing emotional reactivity and emotion regulation in response to positive, negative, and neutral social scenarios. The outcome measure is emotional response rated on a 100-point visual analogue scale (VAS) of discomfort or pleasure.
Time frame: This outcome is assessed only at treatment completion (at week 4)..
Computerized task assessing recognition of emotional facial expressions. The outcome measure is emotion recognition accuracy, defined as the proportion of correctly identified emotional expressions.
Contact information is provided by the study sponsor or research team.
Andreas Elleby Jespersen, PhD
CONTACT
Kamilla Woznica Miskowiak, Professor, DMSc, DPhil
CONTACT
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Other
A Randomized, Placebo-Controlled Pilot Study Evaluating a Probiotic Intervention for Mental Health
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07589114
Behavior, Emotional Regulation
Târgu Mureş, Mureș County, Romania
View Trial DetailsNCT07748715
Basal Ganglia Diseases, Brain Diseases
View Trial DetailsNCT07742384
Healthy Adult Participants
View Trial DetailsNCT07669571
Healthy Adult Participants
Adelaide, South Australia, Australia
View Trial Details